Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Net Income
Bottom-line profit after all expenses, interest, and taxes.
Annovis Bio, Inc.NYSE: ANVS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$17.61M, compared with -$5.54M a year earlier. Trailing-twelve-month net income was -$40.92M.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly net income holds near -$17.61M or moves back toward the trailing-twelve-month quarterly average of -$10.23M.
Sources:Income StatementText generated from reported figures; not investment advice.
Net Income history
USD · from the income statement
- Latest · FY2025
- (28.85M) USD
- Year-over-year change
- -17.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.85M) | -17.3% |
| FY2024 | 2024-12-31 | (24.59M) | +56.2% |
| FY2023 | 2023-12-31 | (56.2M) | -121.9% |
| FY2022 | 2022-12-31 | (25.33M) | -74.8% |
| FY2021 | 2021-12-31 | (14.49M) | — |
Net Income vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's LTM Mar 2026 net income of -$40.92M is the 5th highest of the 6 companies compared; the peer median is -$33.36M.
- Its year-over-year change of -40.8% is the 5th highest of 6, against a peer median of -9.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.31M | +127.6% | — | 32.2% | |
| LTM Mar 2026 | -$24.25M | -23.1% | — | — | |
| LTM Mar 2026 | -$33.36M | +6.0% | — | — | |
| LTM Mar 2026 | -$33.63M | -9.0% | — | — | |
| LTM Mar 2026 | -$40.92M | -40.8% | — | — | |
| LTM Dec 2025 | -$91.71M | -58.4% | — | 345.4% | |
| Peer median (excluding ANVS) | -$33.36M | -9.0% | — | 188.8% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.48M | 16.52M | 38.79M | 20M | 25.22M |
| Selling, General & Admin | 6.06M | 9M | 6.24M | 6.7M | 4.48M |
| Operating Expenses | 14.54M | 25.51M | 45.04M | 26.69M | 29.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (14.5M) | (25.33M) | (56.2M) | (22.74M) | (28.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (14.54M) | (25.51M) | (45.04M) | (26.69M) | (29.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13.34K | 182.71K | 667.9K | 331.85K | 699.06K |
| Interest Expense | 0 | 0 | 0 | 1.85M | 0 |
| Other Income / Expenses | 50.09K | 182.71K | (11.17M) | 2.1M | 841.06K |
| Income Before Tax | (14.49M) | (25.33M) | (56.2M) | (24.59M) | (28.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.49M) | (25.33M) | (56.2M) | (24.59M) | (28.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.90) | (3.10) | (6.23) | (2,018.50) | (1.40) |
| EPS (Diluted) | (1.90) | (3.10) | (6.23) | (2,009.77) | (1.40) |
| Weighted Avg Shares | 7.63M | 8.16M | 9.02M | 12.18M | 20.55M |
| Weighted Avg Shares (Diluted) | 7.63M | 8.16M | 9.02M | 12.24M | 20.55M |
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.